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-Summary
Vincristine has been an important agent in the treatment of especially pediatric
malignancies for four decades. The dose-limiting side effect of vincristine is peripheral
neuropathy resulting in pain, constipation, paresthesias, and impaired motor function.
Besides this neuropathy, other side effects are relatively rnild and no serious long-term
side effects are known, such as second malignancies or infertility. At present, we still
don't know how to prevent or overcome vincristine neuropathy other than by
reducing or interrupting therapy, which might lead to a less optimal oncolytic effect.
Because of its efficacy and relatively mild non-neurotoxic side effects, it is worthwhile
to try to maximize its use as an anticancer agent. Finding lvays to ameliorate vincristine
neuropathy lvould therefore be of great interest.
In this thesis two pharmacological approaches are described to achieve this
goal. First, we hypothesized that neuropathy might be related to vincristine
pharmacokinetics; a higher degree of neuropathy might correlate with a higher
systemic exposure. Therefore, we studied vincristine pharmacokinetics and its relation
to neuropathy in children. Second, we studied recombinant human insulin-l ike growth
factor-l as a potential neuroprotective agent against vincristine induced neuropathy in
a rat model and its potential adverse effects on tumor growth and the antitumor effect
of vincristine in cell l ines and a xenosraft rnouse rnodel.
Background information about vincristine is given in chapter I " Experimental
studies are described in chapters 2 through 6.
In chapter I we review knowledge about vincristine, indicate where
knowledge is lacking, and suggest potential future research areas to enhance its
oncolytic effect and reduce its side effects. Vincristine is an alkaloid, extracted from the
periwinkle plant Catharanthus roseus. It has a broad oncolytic spectrum and high
response rates as single agent and since the early nineteen sixties it has been
incorporated in multidrug protocols for the treatment of especially pediatric
hematological and solid malignancies.
Its dose-limiting side effect is a peripheral, sensory-motor and autonomic
neuropathy, resulting in pain, loss of deep tendon reflexes, constipation, and sometimes
paresthesias, sensory loss and motor weakness, the syndrome of inappropriate
antidiuretic hormone, or cranial nerve dysfunction. The degree of neuropathy is
variable and largely unpredictable. While forrnerly neuropathy was thought to be
totally reversible in recent studies long-term sequelae are recognized. Other side effects
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are relatively mild, like myelosuppression, which makes it easy to combine with other
chemotherapy. Vincristine appears not to induce second malignancies nor lead to
infertility in humans.
Vincristine's most widely known mechanism of action is disruption of
microtubules function. In dividing cells microtubules form the structural elements of
the mitotic spindle and in nerve fibers they are involved in axoplasmic transport
needed for maintenance of the axon. Damage to microtubules of the mitotic spindle by
vincristine results in mitotic arrest of cells, leading to its oncolytic effect. Damage to
microtubules in nerve fibers results in axonal degeneration, leading to peripheral
neuropathy. Knowledge about induction of apoptosis and anti-angiogenesis as
mechanisms of action (and maybe also pathophysiology of neuropathy) is just
emerging. New insights in these aspects might lead to new strategies to optimize the
oncolytic effect of vincristine.
Knowledge about vincristine pharmacokinetics, metabolism and the relation
between pharmacokinetics and the oncolytic effect or neurotoxicity is largely missing.
Information about the relationship between vincristine pharmacokinetics and
pharmacodynamics might contribute to the design of dosage regimens with better
oncolytic effect and less neurotoxicity.
In vitro, several mechanisms of vincristine resistance are recognized, as
multidrug resistance and tubulin changes; their clinical importance is less clear.
Effective and safe ways to modulate vincristine resistance, and thus optimize its
oncolytic effect are still under investigation.
Agents studied to protect against vincristine neuropathy include folinic acid,
vitamin Bl, 86, isaxonine, glutamic acid, gangliosides, and the ACTH analog ORG
2766. Most of these agents were unsuccessful in patients. Recombinant human
insulin-like growth factor I, nerve growth factor, and amifostine seem to be new
promising agents, which need further study to evaluate their neuroprotective ffect.
Experimental studies dealing with vincristine pharmacokinetics and its relation
to neuropathy are described in chapter 2 through 4. Chapters 5 and 6 deal with the
potential neuroprotective and adverse effects of recombinant human insulin-like
growth factor-I.
Chapter 2 describes the high performance liquid chromatography (HPLC)
assay to measure vincristine concentrations in plasma and refinements in the assay
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made to reduce the required sample volume. These make the assay more suitable for
use in small children. The reduction of the required sample volume was realized by
changing the material of the extraction column, and using a more sensitive and
controlled electrochemical detector. These refinements resulted in a reduction of the
sample volume from 1.2 ml to 0.3 ml plasma. A very low limit of quantitation of 0.48
ng/ml according to good laboratoy practice rules could be preserved.
Chapter 3 concerns a descriptive pharmacokinetic study. Intrapatient and
interpatient variability in vincristine disposition and demographic, clinical, and
biochemical characteristics influencing this variability in children are described.
Children were treated for acute lymphoblastic leukemia or non-Hodgkin's lymphoma
according to the Dutch Childhood Leukemia Study Group protocol ALL8 and Wilms'
tumor according to the National Wilms'Tumor Study protocol IV. Vincristine dosage
was 1.5 mg/m2 administered weekiy as iv bolus injection. Pharmacokinetics were
studied after 169 vincristine injections in 32 patients. Plasma concentrations were
measured by HPLC. A two compartment first order model was used to fit to the data
and pharmacokinetic parameters were calculated from this model using the ADAPT II
software. Besides sex, age, and diagnosis, co-medication, liver-, and kidney-function,
total plasma protein, albumin concentration, and platelet count were rnonitored.
Although results show a larger interpatient variability than intrapatient variability in
elimination half-life, total body clearance, apparent volume of distribution, and area
under the concenffation time curve, both were large. Children treated for acute
leukemia and non-Hodgkin's lymphoma had a significantly higher total body clearance
than children treated for Wilms' tumor. Variability however, remained largely
unpredictable.
In chapter 4 the relationship between vincristine pharmacokinetics and clinical
neuropathy in children with acute lymphoblastic leukemia is described. Children were
treated according to the Dutch Childhood Leukemia Study Group Protocol ALL8.
Pharmacokinetics of the first four weekly vincristine injections were studied in the
same way as described for chapter 3. Pharmacokinetics were studied after each of 52
vincristine injections in 13 patients. Degree of clinical neuropathy was scored at
baseline and one week after the fourth vincristine injection according to a modified
WHO scoring system. I Minute vincristine peak concentration, 24 hours plasma
concentration and area under the concentration time curve were related to increase in
WHO score. A higher I minute peak vincristine concentration correlated with a higher
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degree of clinical neuropathy. This correlation was determined by the correlation
between peak concentration and gastrointestinal autonomic neuropathy, not sensory
motor neuropathy.
In chapter 5 we studied the protective effect of recombinant human insulin-like
growth factor-I (rhIGF-I) on vincristine induced sensory motor neuropathy in rats in a
placebo controlled design. Neuropathy was assessed by scoring gait disturbance,
measuring tail-flick latency time, and rota-rod-performance in the light and in the dark.
Neuropathy was scored at baseline, during and upon completion of the 2 week study
period. We found that rhIGF-I ameliorated vincristine induced neuropathy. RhIGF-I
delayed vincristine induced gait disturbance and protected against vincristine induced
decreased rota-rod performance in the dark, but did not protect against vincristine
induced increased tail flick latency time. These results suggest hat rhIGF-I protects
against proprioceptive sensory damage, but not against thermal nocioceptive sensory
damage. The protective effect against motor neuropathy could not be definitely
answered in this study.
In chapter 6 the potential adverse influence of rhIGF-I on cell growth and
cytotoxicity of drugs is described in a preclinical setting. We studied the influence of
rhIGF-I on cell growth and the antitumor effect of vincristine in human
rhabdomyosarcoma cell lines under serum-free and serum-containing conditions. We
found that under serum-containing conditions, in contrast to the less physiological
serum-free conditions, rhIGF-I did not have a significant influence on cell growth. We
could not find a negative influence of rhIGF-I on the antitumor effect of vincristine. To
extend the in vitro data with a model which has more similarity with patients we
studied the same issues in a childhood rhabdomyosarcoma xenograft mouse model.
Results found in vitro were confirmed in vivo.
We conclude that vincristine pharmacokinetics are variable between and within
patients and that tumor type or fieafinent protocol influences part of this variability:
ALL patients have a higher clearance than V/ilms' tumor patients. A higher vincristine
peak concentration correlates with a worse gastrointestinal autonomic neuropathy in
children with acute lymphoblastic leukemia during remission induction treatment.
RhIGF-l was found to ameliorate vincristine induced gait disturbance, and decreased
rota-rod performance in the dark in rats, suggesting that it protects against vincristine
induced proprioceptive sensory neuropathy. We did not find an adverse effect of
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rhIGF-I on tumor growth and the antitumor effect of vincristine in cell lines and
xenograft models.
In summary, results of the research presented in this thesis indicate that
vincristine induced gastrointestinal autonomic neuropathy might be ameliorated by
avoiding high peak concentrations and that sensory neuropathy might be ameliorated
by using rhIGF-I in children. Avoiding high peak vincristine concentrations might be
achieved by giving infusions instead of intravenous bolus injections. Obviously, we
first need to know the relationship between vincristine pharmacokinetics and the
intended, oncolytic effect. Studies to describe this relationship are presently
undertaken. RhIGF-I should be tested in a phase I/II and III study to determine its side
effects, optimal dosage regimen, and neuroprotective effect in children. If we are able
to reduce neuropathy, dose intensity of vincristine can be increased to maximize its
oncolytic effect.
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